세계의 정밀 암 진단 검사 시장 분석(2022-2032년) : 생검 방법별, 최종사용자별, 카테고리별, 암 종류별, 암분자 검사별, 암 영상 검사별 예측, 지역별, 주요 국가의 분석, 주요 기업, 신종 코로나바이러스 감염증(COVID-19)으로부터 회복 시나리오

Title:
Precision Cancer Diagnostic Test Market Report 2022-2032
Forecasts by Biopsy Method (Tissue Biopsy, Liquid Biopsy), by End-user (Hospitals, Clinics, Research Institutes), by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests, Other), by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Pancreatic Cancer, Other), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

The Precision Cancer Diagnostic Test Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advancements in Technologies such as Functional Precision Medicine (FPM) Models

Some of the practical challenges of FPM can be addressed using new technologies created at the intersection of engineering and biology. Technology targeted at simulating the tumour microenvironment, particularly the extracellular matrix, has made significant progress. Organ chips (sometimes referred to as tissue chips or microphysiological systems) are indeed being used to depict cancer inside the tumour microenvironment. Such microfluidics devices, which are typically composed of tissue-specific types of cells, extracellular matrix gels, and cancerous cells, attempt to replicate the molecular and mechanical signals present in human tissue. One of the possible advantages of organ chips is their ability to replicate medicine distribution, pharmacokinetics, pharmacodynamics, and drug toxicity.

Some of the hurdles to the broad use of organ chips in FPM include low drug testing throughput and the necessity for specialised skills to create and operate these devices. Allowing cells to remain in their native habitat throughout pharmaceutical therapy is another way to simulate tumour settings. This comprises medication treatment on individual tumour sections or fine-needle biopsies, wherein immunofluorescent cell death signs can be used to assess drug sensitivity. Its use of drug-containing microdevices which may be implanted directly into patients' tumours is another promising approach for FPM. The medications in such microdevices can affect surrounding tissues, and therapy results in tumours can indeed be evaluated after they've been removed.

What Questions Should You Ask before Buying a Market Research Report?

• How is the precision cancer diagnostic test market evolving?

• What is driving and restraining the precision cancer diagnostic test market?

• How will each precision cancer diagnostic test submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?

• How will the market shares for each precision cancer diagnostic test submarket develop from 2022 to 2032?

• What will be the main driver for the overall market from 2022 to 2032?

• Will leading precision cancer diagnostic test markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?

• Who are the leading players and what are their prospects over the forecast period?

• What are the precision cancer diagnostic test projects for these leading companies?

• How will the industry evolve during the period between 2020 and 2032? What are the implication of precision cancer diagnostic test projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the precision cancer diagnostic test market?

• Where is the precision cancer diagnostic test market heading and how can you ensure you are at the forefront of the market?

• What are the best investment options for new product and service lines?

• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the precision cancer diagnostic test market today, and over the next 10 years:

• Our 602-page report provides 347 tables and 326 charts/graphs exclusively to you.

• The report highlights key lucrative areas in the industry so you can target them - NOW.

• It contains in-depth analyse of global, regional and national sales and growth

• It highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the precision cancer diagnostic test market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects

• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.

• You will find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision cancer diagnostic test prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V" , "L" , "W" and "U" are discussed in this report.

Segments Covered in this report:

Biopsy Method

• Tissue Biopsy
• Liquid Biopsy

End-User

• Hospitals
• Clinics
• Research Institutes

Category

• Cancer Imaging
• Molecular Cancer Testing
• Tumour Marker Immunoassays
• POC Colon Cancer Tests
• Other Categories

Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Pancreatic Cancer
• Other Cancer Type

Cancer Testing

• Blood-Based Molecular Cancer Tests
• HPV Genotyping
• Circulating Tumour Cell (CTC) Tests
• Next-Generation Sequencing Tests

Imaging Test

• Computed Tomography
• Magnetic Resonance Imaging
• Digital & Analog Mammography
• Positron Emission Tomography
• Digital Breast Tomosynthesis
• Molecular Breast Imaging

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America

• U.S.
• Canada
• Mexico

Europe

• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

LAMEA

• Brazil
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Latin America, Middle East and Africa

The report also includes profiles and for some of the leading companies in the Precision Cancer Diagnostic Test Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

• Abbott Laboratories (Abbott)
• Agilent Technologies, Inc.
• AstraZeneca PLC (AstraZeneca)
• Becton, Dickinson and Firm (BD)
• Biocept, Inc.
• Bio-Rad Laboratories Inc.
• Epigenomics AG
• Illumina, Inc. (Illumina)
• Myriad Genetics, Inc. (Myriad)
• Quest Diagnostics Incorporated

Overall world revenue for Precision Cancer Diagnostic Test Market, 2022 to 2032 in terms of value the market will surpass US$15,834 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Precision Cancer Diagnostic Test Market, 2022 to 2032 Market report help you?

In summary, our 602-page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Precision Cancer Diagnostic Test Market, 2022 to 2032 Market, with forecasts for biopsy method, end-user, cancer type, category, molecular cancer testing each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Precision Cancer Diagnostic Test Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market- including company profiles for 10 of the major companies involved in the Precision Cancer Diagnostic Test Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analysis for the Precision Cancer Diagnostic Test Market, 2022 to 2032 and leading companies. You will find data, trends and predictions.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

• 1.1 Introduction to Precision Cancer Diagnostic Test Market
• 1.2 Global Precision Cancer Diagnostic Test Market Overview
• 1.3 What Are the Objectives of this Report?
• 1.4 What is the Scope of the Report?
• 1.5 Precision Cancer Diagnostic Test Market Definition
• 1.6 Why You Should Read this Report
• 1.7 What this Report Delivers
• 1.8 Key Questions Answered by this Analytical Report Include:
• 1.9 Who is this Report for?
• 1.10 Research Methodology
  • 1.10.1 Primary Research
  • 1.10.2 Secondary Research
  • 1.10.3 Market Evaluation & Forecasting Methodology
• 1.11 Frequently Asked Questions (FAQs)
• 1.12 Associated Visiongain Reports
• 1.13 About Visiongain

2 Executive Summary

3 Global Market Dynamics

• 3.1 Market Driving Factors
  • 3.1.1 Emerging FPM Models and Technologies
  • 3.1.2 NGS Technologies Are Rapidly Being Used in Place of Traditional Approaches
  • 3.1.3 Precision Cancer Medicine's Expanding Breadth
• 3.2 Market Restraining Factors
  • 3.2.1 Disadvantages and Limitations of Precision Medicine in Cancer
  • 3.2.2 Cost of Cancer Precision Medicine
  • 3.2.3 Difficulty of Converting Basic Genetic Data into Clinically Relevant and Effective Conclusions
• 3.3 Opportunities in the Global Market
  • 3.3.1 Enhanced Trial Opportunities
  • 3.3.2 Number of Companion Molecular Diagnostic Assays Approved by the FDA is Increasing
  • 3.3.3 Integration of Diagnostic and Treatment Data with Emerging Artificial Intelligence/Machine Learning Platforms
  • 3.3.4 CDx Can Play an Important Function
• 3.4 Challenges in the Global Market
  • 3.4.1 Expense of Testing for Genetic Changes and Subsequent Targeted Therapy
  • 3.4.2 Precision Medicine's Incorporation into Clinical Oncology Operations Has Been Delayed
  • 3.4.3 Technical Difficulties Related with the Development of Precision Medicine's Evidence
• 3.5 SWOT Analysis
• 3.6 PEST Analysis
  • 3.6.1 Political
  • 3.6.2 Economical
  • 3.6.3 Social
  • 3.6.4 Technological
• 3.7 Porters Analysis
  • 3.7.1 Competitive Rivalry
  • 3.7.2 Bargaining Power of Suppliers
  • 3.7.3 Bargaining Power of Customers
  • 3.7.4 Threat of New Entrants
  • 3.7.5 Threat of Substitutes

4 Global Precision Cancer Diagnostic Test Market Analysis

• 4.1 Global Market Outlook
• 4.2 Global Market Size Estimation and Forecast
  • 4.2.1 Pre-COVID-19 Market Scenario
  • 4.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

5 Global Precision Cancer Diagnostic Test Market Analysis by Region

• 5.1 North America
• 5.2 Europe
• 5.3 Asia-Pacific
• 5.4 LAMEA
• 5.5 Regional Market Size Estimation and Forecast
  • 5.5.1 Pre-COVID-19 Market Scenario
  • 5.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

6 Global Market Size Estimation and Forecast by Biopsy Method

• 6.1 Tissue Biopsy
• 6.2 Liquid Biopsy
• 6.3 Pre-COVID-19 Market Scenario
• 6.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7 Global Market Size Estimation and Forecast by End-User

• 7.1 Hospitals
• 7.2 Clinics
• 7.3 Research Institutes
• 7.4 Pre-COVID-19 Market Scenario
• 7.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8 Global Market Size Estimation and Forecast by Category

• 8.1 Cancer Imaging
• 8.2 Molecular Cancer Testing
• 8.3 Tumour Marker Immunoassays
• 8.4 POC Colon Cancer Tests
• 8.5 Others
• 8.6 Pre-COVID-19 Market Scenario
• 8.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9 Global Market Size Estimation and Forecast by Cancer Type

• 9.1 Breast Cancer
• 9.2 Lung Cancer
• 9.3 Colorectal Cancer
• 9.4 Melanoma
• 9.5 Pancreatic Cancer
• 9.6 Other Cancer Types
• 9.7 Pre-COVID-19 Market Scenario
• 9.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10 Global Market Size Estimation and Forecast by Molecular Cancer Testing

• 10.1 Blood-Based Molecular Cancer Tests
• 10.2 HPV Genotyping
• 10.3 Circulating Tumour Cell (CTC) Tests
• 10.4 Next-Generation Sequencing Tests
• 10.5 Pre-COVID-19 Market Scenario
• 10.6 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11 Global Market Size Estimation and Forecast by Cancer Imaging Test

• 11.1 Computed Tomography
• 11.2 Magnetic Resonance Imaging
• 11.3 Digital & Analog Mammography
• 11.4 Positron Emission Tomography
• 11.5 Digital Breast Tomosynthesis
• 11.6 Molecular Breast Imaging
• 11.7 Pre-COVID-19 Market Scenario
• 11.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12 North America Market Size Estimation and Forecast

• 12.1 Market Outlook
• 12.2 North America Market Size Estimation and Forecast
  • 12.2.1 Pre-COVID-19 Market Scenario
  • 12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.3 Country Market Size Estimation and Forecast
  • 12.3.1 Pre-COVID-19 Market Scenario
  • 12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.4 North America Market Size Estimation and Forecast by Biopsy Method
  • 12.4.1 Pre-COVID-19 Market Scenario
  • 12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.5 North America Market Size Estimation and Forecast by End-User
  • 12.5.1 Pre-COVID-19 Market Scenario
  • 12.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.6 North America Market Size Estimation and Forecast by Category
  • 12.6.1 Pre-COVID-19 Market Scenario
  • 12.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.7 North America Market Size Estimation and Forecast by Cancer Type
  • 12.7.1 Pre-COVID-19 Market Scenario
  • 12.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.8 North America Market Size Estimation and Forecast by Molecular Cancer Testing
  • 12.8.1 Pre-COVID-19 Market Scenario
  • 12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.9 North America Market Size Estimation and Forecast by Cancer Imaging Test
  • 12.9.1 Pre-COVID-19 Market Scenario
  • 12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.10 US Precision Cancer Diagnostic Test Market Analysis
  • 12.10.1 Increasing Number of Precision Medicine Clinical Trials in the United States
  • 12.10.2 Pre-COVID-19 Market Scenario
  • 12.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.11 Canada Precision Cancer Diagnostic Test Market Analysis
  • 12.11.1 Adoption of New Systemic Cancer Medicines in Canada is a Multi-Step Process
  • 12.11.2 The Use of Precision Medicine in Canada Will Aid in the Control of Cancer
  • 12.11.3 Pre-COVID-19 Market Scenario
  • 12.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 12.12 Mexico Precision Cancer Diagnostic Test Market Analysis
  • 12.12.1 Developing Successful and Long-Term Precision Oncology Programmes in Mexico in Collaboration with Government Authorities and Institutions
  • 12.12.2 Pre-COVID-19 Market Scenario
  • 12.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13 Europe Market Size Estimation and Forecast

• 13.1 Market Outlook
• 13.2 Europe Market Size Estimation and Forecast
  • 13.2.1 Pre-COVID-19 Market Scenario
  • 13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.3 Country Market Size Estimation and Forecast
  • 13.3.1 Pre-COVID-19 Market Scenario
  • 13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.4 Europe Market Size Estimation and Forecast by Biopsy Method
  • 13.4.1 Pre-COVID-19 Market Scenario
  • 13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.5 Europe Market Size Estimation and Forecast by End-User
  • 13.5.1 Pre-COVID-19 Market Scenario
  • 13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.6 Europe Market Size Estimation and Forecast by Category
  • 13.6.1 Pre-COVID-19 Market Scenario
  • 13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.7 Europe Market Size Estimation and Forecast by Cancer Type
  • 13.7.1 Pre-COVID-19 Market Scenario
  • 13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.8 Europe Market Size Estimation and Forecast by Molecular Cancer Testing
  • 13.8.1 Pre-COVID-19 Market Scenario
  • 13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.9 Europe Market Size Estimation and Forecast by Cancer Imaging Test
  • 13.9.1 Pre-COVID-19 Market Scenario
  • 13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.10 Germany Precision Cancer Diagnostic Test Market Analysis
  • 13.10.1 Rapid Integration of Interdisciplinary Techniques in Germany
  • 13.10.2 Pre-COVID-19 Market Scenario
  • 13.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.11 UK Precision Cancer Diagnostic Test Market Analysis
  • 13.11.1 Expanding Clinical Trails Studies in UK
  • 13.11.2 Investment in Pancreatic Cancer Research
  • 13.11.3 Pre-COVID-19 Market Scenario
  • 13.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.12 France Precision Cancer Diagnostic Test Market Analysis
  • 13.12.1 Pre-COVID-19 Market Scenario
  • 13.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.13 Italy Precision Cancer Diagnostic Test Market Analysis
  • 13.13.1 The Expansion of Precision Oncology in Italy Has Been Impeded by a Lack of Guidelines
  • 13.13.2 Pre-COVID-19 Market Scenario
  • 13.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.14 Spain Precision Cancer Diagnostic Test Market Analysis
  • 13.14.1 Precision Cancer Diagnostic Test Research is Now Focusing on Detecting a Far Larger Number of Mutations in Spain
  • 13.14.2 Pre-COVID-19 Market Scenario
  • 13.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 13.15 Rest of Europe Precision Cancer Diagnostic Test Market Analysis
  • 13.15.1 Pre-COVID-19 Market Scenario
  • 13.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

14 Asia-Pacific Market Size Estimation and Forecast

• 14.1 Market Outlook
• 14.2 Asia-Pacific Market Size Estimation and Forecast
  • 14.2.1 Pre-COVID-19 Market Scenario
  • 14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.3 Country Market Size Estimation and Forecast
  • 14.3.1 Pre-COVID-19 Market Scenario
  • 14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.4 Asia-Pacific Market Size Estimation and Forecast by Biopsy Method
  • 14.4.1 Pre-COVID-19 Market Scenario
  • 14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.5 Asia-Pacific Market Size Estimation and Forecast by End-User
  • 14.5.1 Pre-COVID-19 Market Scenario
  • 14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.6 Asia-Pacific Market Size Estimation and Forecast by Category
  • 14.6.1 Pre-COVID-19 Market Scenario
  • 14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.7 Asia-Pacific Market Size Estimation and Forecast by Cancer Type
  • 14.7.1 Pre-COVID-19 Market Scenario
  • 14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.8 Asia-Pacific Market Size Estimation and Forecast by Molecular Cancer Testing
  • 14.8.1 Pre-COVID-19 Market Scenario
  • 14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.9 Asia-Pacific Market Size Estimation and Forecast by Cancer Imaging Test
  • 14.9.1 Pre-COVID-19 Market Scenario
  • 14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.10 China Precision Cancer Diagnostic Test Market Analysis
  • 14.10.1 Large-Scale Deployment of Self-Powered Triboelectric Nanogenerator (TENG) Devices Has Promise for Cancer Treatment
  • 14.10.2 Pre-COVID-19 Market Scenario
  • 14.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.11 India Precision Cancer Diagnostic Test Market Analysis
  • 14.11.1 Pre-COVID-19 Market Scenario
  • 14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.12 Japan Precision Cancer Diagnostic Test Market Analysis
  • 14.12.1 Precision Oncology Is Revolutionising Cancer Patient Treatment in Japan, but Many Hospitals Are Having Trouble Putting it into Practise
  • 14.12.2 Pre-COVID-19 Market Scenario
  • 14.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.13 South Korea Precision Cancer Diagnostic Test Market Analysis
  • 14.13.1 Various Precision Medicine Collaborations Are Taking Place in South Korea
  • 14.13.2 Pre-COVID-19 Market Scenario
  • 14.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.14 Australia Precision Cancer Diagnostic Test Market Analysis
  • 14.14.1 Pre-COVID-19 Market Scenario
  • 14.14.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 14.15 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market Analysis
  • 14.15.1 Pre-COVID-19 Market Scenario
  • 14.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

15 LAMEA Market Size Estimation and Forecast

• 15.1 Market Outlook
• 15.2 LAMEA Market Size Estimation and Forecast
  • 15.2.1 Pre-COVID-19 Market Scenario
  • 15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.3 Country Market Size Estimation and Forecast
  • 15.3.1 Pre-COVID-19 Market Scenario
  • 15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.4 LAMEA Market Size Estimation and Forecast by Biopsy Method
  • 15.4.1 Pre-COVID-19 Market Scenario
  • 15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.5 LAMEA Market Size Estimation and Forecast by End-User
  • 15.5.1 Pre-COVID-19 Market Scenario
  • 15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.6 LAMEA Market Size Estimation and Forecast by Category
  • 15.6.1 Pre-COVID-19 Market Scenario
  • 15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.7 LAMEA Market Size Estimation and Forecast by Cancer Type
  • 15.7.1 Pre-COVID-19 Market Scenario
  • 15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.8 LAMEA Market Size Estimation and Forecast by Molecular Cancer Testing
  • 15.8.1 Pre-COVID-19 Market Scenario
  • 15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.9 LAMEA Market Size Estimation and Forecast by Cancer Imaging Test
  • 15.9.1 Pre-COVID-19 Market Scenario
  • 15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.10 Brazil Precision Cancer Diagnostic Test Market Analysis
  • 15.10.1 Brazil is Making Significant Contributions to Cancer Research
  • 15.10.2 Brazil Can Easily Become a Model for Other Latin American Countries, in Terms of the Potential Benefits of Precision Medicine
  • 15.10.3 Pre-COVID-19 Market Scenario
  • 15.10.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.11 South Africa Precision Cancer Diagnostic Test Market Analysis
  • 15.11.1 To Develop Precision Medicine Requires More Specialised Professionals in South Africa
  • 15.11.2 Pre-COVID-19 Market Scenario
  • 15.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.12 Saudi Arabia Precision Cancer Diagnostic Test Market Analysis
  • 15.12.1 Precision Cancer Diagnostic Test Has Significantly Revolutionised the Cancer Diagnostic and Treatment Environment in Saudi Arabia
  • 15.12.2 Pre-COVID-19 Market Scenario
  • 15.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.13 Turkey Precision Cancer Diagnostic Test Market Analysis
  • 15.13.1 Pre-COVID-19 Market Scenario
  • 15.13.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.14 UAE Precision Cancer Diagnostic Test Market Analysis
  • 15.14.1 Companies in the UAE Utilising New Collaboration Strategies to Increase Precision Cancer Diagnostic Test
  • 15.14.2 Pre-COVID-19 Market Scenario
  • 15.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
• 15.15 Rest of LAMEA Precision Cancer Diagnostic Test Market Analysis
  • 15.15.1 Pre-COVID-19 Market Scenario
  • 15.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

16 Company Profiles

• 16.1 Bio-Rad Laboratories Inc.
  • 16.1.1 Company Snapshot
  • 16.1.2 Company Overview
  • 16.1.3 Company Financial Profile
  • 16.1.4 Company Product Benchmarking
  • 16.1.5 Company Recent Developments
• 16.2 Illumina Inc
  • 16.2.1 Company Snapshot
  • 16.2.2 Company Overview
  • 16.2.3 Company Financial Profile
  • 16.2.4 Company Product Benchmarking
  • 16.2.5 Company Recent Developments
• 16.3 Biocept Inc.
  • 16.3.1 Company Snapshot
  • 16.3.2 Company Overview
  • 16.3.3 Company Financial Profile
  • 16.3.4 Company Product Benchmarking
  • 16.3.5 Company Recent Developments
• 16.4 Epigenomics AG
  • 16.4.1 Company Snapshot
  • 16.4.2 Company Overview
  • 16.4.3 Company Financial Profile
  • 16.4.4 Company Product Benchmarking
• 16.5 AstraZeneca plc
  • 16.5.1 Company Snapshot
  • 16.5.2 Company Overview
  • 16.5.3 Company Financial Profile
  • 16.5.4 Company Product Benchmarking
  • 16.5.5 Company Recent Developments
• 16.6 Myriad Genetics Inc.
  • 16.6.1 Company Snapshot
  • 16.6.2 Company Overview
  • 16.6.3 Company Product Benchmarking
  • 16.6.4 Company Recent Developments
• 16.7 Quest Diagnostics Inc.
  • 16.7.1 Company Snapshot
  • 16.7.2 Company Overview
  • 16.7.3 Company Financial Profile
  • 16.7.4 Company Product Benchmarking
  • 16.7.5 Company Recent Developments
• 16.8 Abbott Laboratories
  • 16.8.1 Company Snapshot
  • 16.8.2 Company Overview
  • 16.8.3 Company Financial Profile
  • 16.8.4 Company Product Benchmarking
  • 16.8.5 Company Recent Developments
• 16.9 Agilent Technologies Inc.
  • 16.9.1 Company Snapshot
  • 16.9.2 Company Overview
  • 16.9.3 Company Financial Profile
  • 16.9.4 Company Product Benchmarking
  • 16.9.5 Company Recent Developments
• 16.10 Becton Dickinson and Co.
  • 16.10.1 Company Snapshot
  • 16.10.2 Company Overview
  • 16.10.3 Company Financial Profile
  • 16.10.4 Company Product Benchmarking
  • 16.10.5 Company Recent Developments

17 Conclusion and Recommendations

• 17.1 Conclusion Summary
• 17.2 Recommendations